Contact
searchSearch
HMP Global

Multiple Myeloma Topic Center

Featured Article

News
Higher Health Care Burden in Multiple Myeloma With Extramedullary Disease, Study Finds
12/02/2025
Grace Taylor, MS, MA
A study presented at the 22nd International Myeloma Society (IMS) Annual Meeting shows that extramedullary disease significantly increases health care utilization and costs for patients with triple-class–exposed (TCE) relapsed/refractory...
A study presented at the 22nd International Myeloma Society (IMS) Annual Meeting shows that extramedullary disease significantly increases health care utilization and costs for patients with triple-class–exposed (TCE) relapsed/refractory...
A study presented at the 22nd...
12/02/2025
First Report Managed Care
News
High Health Care Costs Persist for Relapsed/Refractory Multiple Myeloma in the US
11/17/2025
Grace Taylor, MS, MA
A US claims study reveals that patients with relapsed or refractory multiple myeloma (RRMM) who discontinue lenalidomide face overwhelming monthly health care costs driven primarily by drug and infusion expenses.
A US claims study reveals that patients with relapsed or refractory multiple myeloma (RRMM) who discontinue lenalidomide face overwhelming monthly health care costs driven primarily by drug and infusion expenses.
A US claims study reveals that...
11/17/2025
First Report Managed Care
News
Daratumumab Quadruplet Improves Depth of Response in Older Myeloma
11/10/2025
Hannah Musick
In a pooled analysis of GRIFFIN and PERSEUS, transplant-eligible adults aged ≥65 years with newly diagnosed multiple myeloma who received daratumumab-VRd followed by D-R achieved deeper responses and higher MRD-negativity with a trend toward...
In a pooled analysis of GRIFFIN and PERSEUS, transplant-eligible adults aged ≥65 years with newly diagnosed multiple myeloma who received daratumumab-VRd followed by D-R achieved deeper responses and higher MRD-negativity with a trend toward...
In a pooled analysis of GRIFFIN...
11/10/2025
First Report Managed Care
Jagannath
CONFERENCE COVERAGE
The Path to Cure in Multiple Myeloma: How Emerging Therapies Are Changing the Landscape
10/17/2025
Sundar Jagannath, MBBS
At SOHO 2025, Sundar Jagannath, MBBS, joined Noopur Raje, MD, Krina Patel, MD, and other experts to discuss groundbreaking advances in CAR T-cell, bispecific, and trispecific therapies that are transforming multiple myeloma from a chronic...
At SOHO 2025, Sundar Jagannath, MBBS, joined Noopur Raje, MD, Krina Patel, MD, and other experts to discuss groundbreaking advances in CAR T-cell, bispecific, and trispecific therapies that are transforming multiple myeloma from a chronic...
At SOHO 2025, Sundar Jagannath,...
10/17/2025
First Report Managed Care
News
Patients and Clinicians Prioritize Scientific Innovation and Treatment-Free Living in Multiple Myeloma Care
10/10/2025
Hannah Musick
Both patients and providers ranked progression-free survival as the most important treatment attribute in multiple myeloma, but also strongly valued the ability to live without ongoing treatment and the presence of scientific innovation.
Both patients and providers ranked progression-free survival as the most important treatment attribute in multiple myeloma, but also strongly valued the ability to live without ongoing treatment and the presence of scientific innovation.
Both patients and providers...
10/10/2025
First Report Managed Care
Lonial
CONFERENCE COVERAGE
SOHO 2025 Highlights: Redefining Risk and Treatment in Smoldering Multiple Myeloma
10/10/2025
Sagar Lonial, MD
Dr Sagar Lonial discusses his SOHO 2025 case presentation on evolving definitions of high-risk smoldering multiple myeloma, the growing evidence for early intervention, and how innovations such as CAR T-cell therapies and bispecific...
Dr Sagar Lonial discusses his SOHO 2025 case presentation on evolving definitions of high-risk smoldering multiple myeloma, the growing evidence for early intervention, and how innovations such as CAR T-cell therapies and bispecific...
Dr Sagar Lonial discusses his...
10/10/2025
First Report Managed Care
News
No Increased Multiple Myeloma Risk Found With Biologic or Targeted DMARD Use in Veterans With Rheumatoid Arthritis
10/07/2025
Grace Taylor, MS, MA
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health...
10/07/2025
First Report Managed Care
Usmani Headshot
Conference Coverage
Rethinking the Risk: Evolving Strategies for High-Risk Smoldering Myeloma at SOHO 2025
09/08/2025
Saad Z. Usmani, MD, FACP
Dr Saad Usmani, chief of the myeloma service at Memorial Sloan Kettering Cancer Center, explores the evolving debate on early intervention for high-risk smoldering multiple myeloma, highlighting pivotal trial data and its potential to reshape...
Dr Saad Usmani, chief of the myeloma service at Memorial Sloan Kettering Cancer Center, explores the evolving debate on early intervention for high-risk smoldering multiple myeloma, highlighting pivotal trial data and its potential to reshape...
Dr Saad Usmani, chief of the...
09/08/2025
First Report Managed Care
Martin
Conference Coverage
What’s Next in Multiple Myeloma: Smoldering, High-Risk, and Frontline Therapy
09/03/2025
Thomas G. Martin, III, MD
Dr Thomas Martin previews his SOHO 2025 session and explores the pressing next questions in multiple myeloma, including when to treat smoldering disease, how to better define and manage high-risk patients, and how innovations like bispecifics...
Dr Thomas Martin previews his SOHO 2025 session and explores the pressing next questions in multiple myeloma, including when to treat smoldering disease, how to better define and manage high-risk patients, and how innovations like bispecifics...
Dr Thomas Martin previews his...
09/03/2025
First Report Managed Care
Raje Headshot
Conference Coverage
CAR T-Cell Therapy in Myeloma: A New Era of Early Intervention
09/02/2025
Noopur S. Raje, MD
At SOHO 2025, Dr Noopur Raje will present a cutting-edge overview of CAR T-cell therapy in multiple myeloma, highlighting long-term efficacy data, novel targets like GPRC5D, emerging dual-targeting and in vivo CAR strategies, and the evolving...
At SOHO 2025, Dr Noopur Raje will present a cutting-edge overview of CAR T-cell therapy in multiple myeloma, highlighting long-term efficacy data, novel targets like GPRC5D, emerging dual-targeting and in vivo CAR strategies, and the evolving...
At SOHO 2025, Dr Noopur Raje...
09/02/2025
First Report Managed Care
News
DKRd Induction Yields Superior MRD Negativity in NDMM, Regardless of Transplant
07/23/2025
Grace Taylor, MS, MA
The ADVANCE trial shows that adding daratumumab to carfilzomib-lenalidomide-dexamethasone (KRd) significantly improves minimal residual disease (MRD) negativity in newly diagnosed multiple myeloma, according to a study presented at the 2025...
The ADVANCE trial shows that adding daratumumab to carfilzomib-lenalidomide-dexamethasone (KRd) significantly improves minimal residual disease (MRD) negativity in newly diagnosed multiple myeloma, according to a study presented at the 2025...
The ADVANCE trial shows that...
07/23/2025
First Report Managed Care

Newsfeed

News
Higher Health Care Burden in Multiple Myeloma With Extramedullary Disease, Study Finds
12/02/2025
Grace Taylor, MS, MA
A study presented at the 22nd International Myeloma Society (IMS) Annual Meeting shows that extramedullary disease significantly increases health care utilization and costs for patients with triple-class–exposed (TCE) relapsed/refractory...
A study presented at the 22nd International Myeloma Society (IMS) Annual Meeting shows that extramedullary disease significantly increases health care utilization and costs for patients with triple-class–exposed (TCE) relapsed/refractory...
A study presented at the 22nd...
12/02/2025
First Report Managed Care
News
High Health Care Costs Persist for Relapsed/Refractory Multiple Myeloma in the US
11/17/2025
Grace Taylor, MS, MA
A US claims study reveals that patients with relapsed or refractory multiple myeloma (RRMM) who discontinue lenalidomide face overwhelming monthly health care costs driven primarily by drug and infusion expenses.
A US claims study reveals that patients with relapsed or refractory multiple myeloma (RRMM) who discontinue lenalidomide face overwhelming monthly health care costs driven primarily by drug and infusion expenses.
A US claims study reveals that...
11/17/2025
First Report Managed Care
News
Daratumumab Quadruplet Improves Depth of Response in Older Myeloma
11/10/2025
Hannah Musick
In a pooled analysis of GRIFFIN and PERSEUS, transplant-eligible adults aged ≥65 years with newly diagnosed multiple myeloma who received daratumumab-VRd followed by D-R achieved deeper responses and higher MRD-negativity with a trend toward...
In a pooled analysis of GRIFFIN and PERSEUS, transplant-eligible adults aged ≥65 years with newly diagnosed multiple myeloma who received daratumumab-VRd followed by D-R achieved deeper responses and higher MRD-negativity with a trend toward...
In a pooled analysis of GRIFFIN...
11/10/2025
First Report Managed Care
News
Patients and Clinicians Prioritize Scientific Innovation and Treatment-Free Living in Multiple Myeloma Care
10/10/2025
Hannah Musick
Both patients and providers ranked progression-free survival as the most important treatment attribute in multiple myeloma, but also strongly valued the ability to live without ongoing treatment and the presence of scientific innovation.
Both patients and providers ranked progression-free survival as the most important treatment attribute in multiple myeloma, but also strongly valued the ability to live without ongoing treatment and the presence of scientific innovation.
Both patients and providers...
10/10/2025
First Report Managed Care
News
No Increased Multiple Myeloma Risk Found With Biologic or Targeted DMARD Use in Veterans With Rheumatoid Arthritis
10/07/2025
Grace Taylor, MS, MA
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health...
10/07/2025
First Report Managed Care
News
DKRd Induction Yields Superior MRD Negativity in NDMM, Regardless of Transplant
07/23/2025
Grace Taylor, MS, MA
The ADVANCE trial shows that adding daratumumab to carfilzomib-lenalidomide-dexamethasone (KRd) significantly improves minimal residual disease (MRD) negativity in newly diagnosed multiple myeloma, according to a study presented at the 2025...
The ADVANCE trial shows that adding daratumumab to carfilzomib-lenalidomide-dexamethasone (KRd) significantly improves minimal residual disease (MRD) negativity in newly diagnosed multiple myeloma, according to a study presented at the 2025...
The ADVANCE trial shows that...
07/23/2025
First Report Managed Care
News
Peripheral Residual Disease Monitoring Signals Progression Risk in Multiple Myeloma
10/18/2024
Jolynn Tumolo
Peripheral residual disease identified using next-generation flow in patients with transplant-eligible multiple myeloma was associated with a 13-fold increased risk of progression or death, according to a clinical trial update published...
Peripheral residual disease identified using next-generation flow in patients with transplant-eligible multiple myeloma was associated with a 13-fold increased risk of progression or death, according to a clinical trial update published...
Peripheral residual disease...
10/18/2024
First Report Managed Care
News
Combination Therapy for Multiple Myeloma Emerging as Standard of Care
12/22/2022
Edan Stanley
Authors shared updated efficacy and safety data from the phase 3 CANDOR study in which patients with relapsed or refractory multiple myeloma were treated with two combination therapy options.
Authors shared updated efficacy and safety data from the phase 3 CANDOR study in which patients with relapsed or refractory multiple myeloma were treated with two combination therapy options.
Authors shared updated efficacy...
12/22/2022
First Report Managed Care
News
Stem Cell Yield Adequate for Transplant After 4 Cycles of Daratumumab, Lenalidomide Quadruplet Induction for MM
12/21/2022
Jolynn Tumolo
Researchers reviewed data from the MASTER and GRIFFIN trials to determine whether patients could undergo stem cell transplants after receiving induction therapy that included daratumumab and lenolidamide. 
Researchers reviewed data from the MASTER and GRIFFIN trials to determine whether patients could undergo stem cell transplants after receiving induction therapy that included daratumumab and lenolidamide. 
Researchers reviewed data from...
12/21/2022
First Report Managed Care
News
Real-World Treatment Patterns, Outcomes in Patients With Double- and Triple-Class R/R Multiple Myeloma
12/15/2022
Jolynn Tumolo
Researchers studied a heavily pretreated patient population to determine which drugs were being administered, as well as their impact on overall survival.
Researchers studied a heavily pretreated patient population to determine which drugs were being administered, as well as their impact on overall survival.
Researchers studied a heavily...
12/15/2022
First Report Managed Care
News
US Observational Data Show Variable Real-World Outcomes With JAK Inhibitors in RA
01/19/2026
Juliet Gallagher
Real-world evidence (RWE) is increasingly used to complement randomized controlled trial data in rheumatoid arthritis treatment decision-making. A new study synthesized observational studies evaluating the real-world effectiveness of Janus...
Real-world evidence (RWE) is increasingly used to complement randomized controlled trial data in rheumatoid arthritis treatment decision-making. A new study synthesized observational studies evaluating the real-world effectiveness of Janus...
Real-world evidence (RWE) is...
01/19/2026
First Report Managed Care
News
Miami Drug Wholesaler Enters Federal Opioid Deferred Prosecution Agreement
01/14/2026
Hannah Musick
A Miami pharmaceutical wholesaler admitted to knowingly supplying millions of opioid pills to Houston-area pill mill pharmacies under a federal deferred prosecution agreement, highlighting continued enforcement against opioid diversion across...
A Miami pharmaceutical wholesaler admitted to knowingly supplying millions of opioid pills to Houston-area pill mill pharmacies under a federal deferred prosecution agreement, highlighting continued enforcement against opioid diversion across...
A Miami pharmaceutical...
01/14/2026
First Report Managed Care
News
House Passes Bill to Extend ACA Premium Tax Credits
01/13/2026
Hannah Musick
The US House has advanced a bipartisan-backed bill to extend enhanced Affordable Care Act (ACA) premium tax credits, setting up a high-stakes Senate debate with major implications for insurance affordability and patient access to care.
The US House has advanced a bipartisan-backed bill to extend enhanced Affordable Care Act (ACA) premium tax credits, setting up a high-stakes Senate debate with major implications for insurance affordability and patient access to care.
The US House has advanced a...
01/13/2026
First Report Managed Care
News
Specialist Access Eliminates Racial Gaps in Rheumatoid Arthritis DMARD Use
01/12/2026
Lisa Kuhns, PhD, MD
Racial inequities in access to modern rheumatoid arthritis (RA) therapies persist across the United States, but disappear among patients who reach rheumatology care, according to study results published in The Journal of Rheumatology.
Racial inequities in access to modern rheumatoid arthritis (RA) therapies persist across the United States, but disappear among patients who reach rheumatology care, according to study results published in The Journal of Rheumatology.
Racial inequities in access to...
01/12/2026
First Report Managed Care
News
CMS Establishes Office of Rural Health Transformation Nationwide
01/09/2026
Grace Taylor, MS, MA
The Centers for Medicare & Medicaid Services (CMS) has formally launched the Office of Rural Health Transformation, creating a dedicated hub to oversee a $50 billion, 5-year effort to strengthen rural health systems and expand access to care...
The Centers for Medicare & Medicaid Services (CMS) has formally launched the Office of Rural Health Transformation, creating a dedicated hub to oversee a $50 billion, 5-year effort to strengthen rural health systems and expand access to care...
The Centers for Medicare &...
01/09/2026
First Report Managed Care
News
HHS Revises Childcare Payment Rules, Restoring Attendance-Based Billing
01/05/2026
Hannah Musick
HHS announced it will roll back childcare payment rules, restore attendance-based billing, and revise oversight requirements for federally funded programs.
HHS announced it will roll back childcare payment rules, restore attendance-based billing, and revise oversight requirements for federally funded programs.
HHS announced it will roll back...
01/05/2026
First Report Managed Care
News
AI Navigator Launched to Support Medicaid and SNAP Members Amid Policy Shifts
12/22/2025
Hannah Musick
Social health platform Pyx Health has launched an AI-driven navigator aimed at helping US Medicaid and Supplemental Nutrition Assistance Program (SNAP) beneficiaries comply with new policy requirements under the One Big Beautiful Bill Act...
Social health platform Pyx Health has launched an AI-driven navigator aimed at helping US Medicaid and Supplemental Nutrition Assistance Program (SNAP) beneficiaries comply with new policy requirements under the One Big Beautiful Bill Act...
Social health platform Pyx...
12/22/2025
First Report Managed Care
News
CMS Unveils LEAD Model to Succeed ACO REACH in 2027
12/19/2025
Grace Taylor, MS, MA
The Centers for Medicare & Medicaid Services (CMS) is set to replace the Accountable Care Organization (ACO) REACH model with its longest-ever accountable care demonstration, a 10-year Long-Term Enhanced ACO Design (LEAD) model aimed at...
The Centers for Medicare & Medicaid Services (CMS) is set to replace the Accountable Care Organization (ACO) REACH model with its longest-ever accountable care demonstration, a 10-year Long-Term Enhanced ACO Design (LEAD) model aimed at...
The Centers for Medicare &...
12/19/2025
First Report Managed Care
News
Rising Denials and Payer Audits Intensify Financial Strain on Hospitals in 2025
12/16/2025
Lisa Kuhns, PhD, MD
Hospitals are facing rising financial pressure as denial amounts and payer audits continue to climb in 2025, signaling an unsustainable trend for many health systems, according to a new report from billing compliance and revenue integrity...
Hospitals are facing rising financial pressure as denial amounts and payer audits continue to climb in 2025, signaling an unsustainable trend for many health systems, according to a new report from billing compliance and revenue integrity...
Hospitals are facing rising...
12/16/2025
First Report Managed Care
News
Racial and Ethnic Differences Shape NSCLC Treatment Decision-Making in the US
12/11/2025
Hannah Musick
A new US survey study reveals significant racial and ethnic differences in how patients with non–small cell lung cancer (NSCLC) and their oncologists prioritize treatment goals, cultural needs, and shared decision-making, underscoring the...
A new US survey study reveals significant racial and ethnic differences in how patients with non–small cell lung cancer (NSCLC) and their oncologists prioritize treatment goals, cultural needs, and shared decision-making, underscoring the...
A new US survey study reveals...
12/11/2025
First Report Managed Care

Insights

Jagannath
CONFERENCE COVERAGE
The Path to Cure in Multiple Myeloma: How Emerging Therapies Are Changing the Landscape
10/17/2025
Sundar Jagannath, MBBS
At SOHO 2025, Sundar Jagannath, MBBS, joined Noopur Raje, MD, Krina Patel, MD, and other experts to discuss groundbreaking advances in CAR T-cell, bispecific, and trispecific therapies that are transforming multiple myeloma from a chronic...
At SOHO 2025, Sundar Jagannath, MBBS, joined Noopur Raje, MD, Krina Patel, MD, and other experts to discuss groundbreaking advances in CAR T-cell, bispecific, and trispecific therapies that are transforming multiple myeloma from a chronic...
At SOHO 2025, Sundar Jagannath,...
10/17/2025
First Report Managed Care
Lonial
CONFERENCE COVERAGE
SOHO 2025 Highlights: Redefining Risk and Treatment in Smoldering Multiple Myeloma
10/10/2025
Sagar Lonial, MD
Dr Sagar Lonial discusses his SOHO 2025 case presentation on evolving definitions of high-risk smoldering multiple myeloma, the growing evidence for early intervention, and how innovations such as CAR T-cell therapies and bispecific...
Dr Sagar Lonial discusses his SOHO 2025 case presentation on evolving definitions of high-risk smoldering multiple myeloma, the growing evidence for early intervention, and how innovations such as CAR T-cell therapies and bispecific...
Dr Sagar Lonial discusses his...
10/10/2025
First Report Managed Care
Headshot of Dr Hira Shaikh, University of Iowa
Interview
Hispanic Ethnicity Associated With Worse Multiple Myeloma Outcomes, Study Shows
01/19/2023
Maria Asimopoulos
Hira Shaikh, MD, assistant professor of hematology, oncology, and bone marrow transplant, University of Iowa Hospitals and Clinics, walks through the details of her study which compared multiple myeloma survival outcomes among Hispanic vs...
Hira Shaikh, MD, assistant professor of hematology, oncology, and bone marrow transplant, University of Iowa Hospitals and Clinics, walks through the details of her study which compared multiple myeloma survival outcomes among Hispanic vs...
Hira Shaikh, MD, assistant...
01/19/2023
First Report Managed Care
Headshot of Joshua Richter, MD, Mount Sinai
Interview
Analyzing First-line Therapy for Multiple Myeloma: Real-World Data Differs From Trials
10/18/2022
Maria Asimopoulos
Joshua Richter, MD, associate professor of medicine, hematology, and oncology, Tisch Cancer Institute, Icahn School of Medicine, Mount Sinai, reviews real-world data presented at the SOHO 2022 Annual Meeting in which combination bortezomib,...
Joshua Richter, MD, associate professor of medicine, hematology, and oncology, Tisch Cancer Institute, Icahn School of Medicine, Mount Sinai, reviews real-world data presented at the SOHO 2022 Annual Meeting in which combination bortezomib,...
Joshua Richter, MD, associate...
10/18/2022
First Report Managed Care

Behind the Bill

Behind the Bill
The Senate’s $3 Trillion Deal. Tax Relief Now, Medicaid Coverage Loss Later?
07/02/2025
Katie Hayes, MJ
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After...
07/02/2025
First Report Managed Care
Behind the Bill
When a Cap Isn’t Just a Cap: How a Provider Tax Proposal Could Reshape Medicaid Financing
06/25/2025
Katie Hayes, MJ
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most...
06/25/2025
First Report Managed Care
Behind the Bill
Rewriting the Safety Net? Inside the Senate’s Changes to Medicaid and the ACA
06/18/2025
Katie Hayes, MJ
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve...
06/18/2025
First Report Managed Care
Behind the Bill
How States Might Respond to the One Big Beautiful Bill Act
06/11/2025
Katie Hayes, MJ
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill...
06/11/2025
First Report Managed Care
Behind the Bill
Is the Affordable Care Act on the Chopping Block? What the One Big Beautiful Bill Act Tells Us.
06/04/2025
Katie Hayes, MJ
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of...
06/04/2025
First Report Managed Care
Behind the Bill
From House to Senate: The Journey of Cutting Medicaid
05/28/2025
Katie Hayes, MJ
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of...
05/28/2025
First Report Managed Care
Behind the Bill
Eligibility, Paperwork, and Penalties: The Not-So-Hidden Costs of Medicaid ‘Reform’
05/21/2025
Katie Hayes, MJ
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week...
05/21/2025
First Report Managed Care
Behind the Bill
A Busy Week in Drug Pricing Policy: Aligning US Drug Prices With Global Standards?
05/14/2025
Katie Hayes, MJ
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for...
05/14/2025
First Report Managed Care
BEHIND THE BILL
When Agencies Lose Power: How 3 Seismic Shifts are Transforming Pharmaceutical Regulation
05/07/2025
Katie Hayes, MJ
In the span of just 9 months, the landscape of administrative law has undergone a transformation so profound that pharmaceutical executives, health care providers, and patients alike are struggling to navigate the new terrain. The Supreme...
In the span of just 9 months, the landscape of administrative law has undergone a transformation so profound that pharmaceutical executives, health care providers, and patients alike are struggling to navigate the new terrain. The Supreme...
In the span of just 9 months,...
05/07/2025
First Report Managed Care
Behind the Bill
The Medicare Paradox, Part 3: Strategic Trade Doesn’t Have to be a Zero-Sum Game
05/07/2025
Katie Hayes, MJ
Over the past 2 weeks, I’ve examined the growing friction between the Section 232 pharmaceutical tariff investigations and the Medicare drug pricing reforms authorized by the Inflation Reduction Act (IRA). These 2 policy agendas—industrial...
Over the past 2 weeks, I’ve examined the growing friction between the Section 232 pharmaceutical tariff investigations and the Medicare drug pricing reforms authorized by the Inflation Reduction Act (IRA). These 2 policy agendas—industrial...
Over the past 2 weeks, I’ve...
05/07/2025
First Report Managed Care

Trending Articles

Cover Story
Federal Oversight of Managed Care a Priority
03/01/2024
Mary Beth Nierengarten
In 2022, Medicare Advantage plans covered 50% of Medicare enrollees, costing the federal government $403 billion, while 81% of Medicaid enrollees received care through managed care for $254 billion. The Health and Human Services Office of...
In 2022, Medicare Advantage plans covered 50% of Medicare enrollees, costing the federal government $403 billion, while 81% of Medicaid enrollees received care through managed care for $254 billion. The Health and Human Services Office of...
In 2022, Medicare Advantage...
03/01/2024
First Report Managed Care
News
Fecal Microbiota Transplant for Patients With IBD and rCDI: Safety and Efficacy
03/28/2024

Emry Lloyd

Emry Lloyd
Patients with recurrent Clostridioides difficile infection have shown significant results when administered a fecal microbiota transplant. This study evaluated the safety and efficacy of using a fecal microbiota transplant for patients with...
Patients with recurrent Clostridioides difficile infection have shown significant results when administered a fecal microbiota transplant. This study evaluated the safety and efficacy of using a fecal microbiota transplant for patients with...
Patients with recurrent...
03/28/2024
First Report Managed Care
News
Analysis Shows Proposed CMS ‘Best Price’ Rule May Increase Rebate Liability, Impacting Medicaid
04/26/2024
Dean Celia
A proposed rule from Centers for Medicare & Medicaid Services (CMS), “Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program,” has been in the spotlight recently. Major health...
A proposed rule from Centers for Medicare & Medicaid Services (CMS), “Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program,” has been in the spotlight recently. Major health...
A proposed rule from Centers for...
04/26/2024
First Report Managed Care
Carmine DeNardo Headshot
Interview
The Evolving Landscape of Specialty Pharmacy: PROs and PROMs Insights
05/28/2024
Following Asembia 2024, an expert emphasizes the critical role of specialty pharmacies in patient care and highlights payers' increasing coverage of high-cost biologics and oncology medications, driven by value-based contracts and real-world...
Following Asembia 2024, an expert emphasizes the critical role of specialty pharmacies in patient care and highlights payers' increasing coverage of high-cost biologics and oncology medications, driven by value-based contracts and real-world...
Following Asembia 2024, an...
05/28/2024
First Report Managed Care
Blog
An IRA Progress Report: What We Know (and Don’t Know) Two Years in
07/09/2024
In this blog the HMP Market Access Intelligence team breaks down the knowns and unknowns of the Inflation Reduction Act's impact on drug price negotiations and what the future may hold.
In this blog the HMP Market Access Intelligence team breaks down the knowns and unknowns of the Inflation Reduction Act's impact on drug price negotiations and what the future may hold.
In this blog the HMP Market...
07/09/2024
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use